Alterations in skin immune response throughout chronic UVB irradiation-skin cancer development and prevention by naproxen.
Skin exposure to UVB radiation has been reported to produce both a significant inflammatory response and marked immunosuppression. This work was aimed to evaluate whether the response of murine skin to an acute UVB dose was modified by pre-exposure to chronic UVB irradiation and by topical treatment with naproxen, a nonsteroidal anti-inflammatory drug. Moreover, the effect of naproxen on the incidence of UV-induced skin tumors was studied. Prostaglandin E(2) (PGE(2)) and tumor necrosis factor alpha (TNF-alpha) levels were increased 96 h post-UVB in acutely irradiated animals and both mediators were modified by topical naproxen application-PGE(2) was decreased while TNF-alpha was increased. Such inflammatory response was suppressed when mice were chronically irradiated. Naproxen application on chronically irradiated mice reduced the incidence of tumor lesions. Taken together, our data suggest that chronic UVB irradiation generates an immunosuppressive state that prevents skin cells from responding normally to an acute irradiation challenge, thus impairing the protective effect of TNF-alpha against skin tumor development. Furthermore, reduction in the incidence of tumor lesions by naproxen may be due to its ability to increase TNF-alpha levels as well as to decrease PGE(2).
González Maglio
Daniel H
DH
Immunology Department, Pharmacy and Biochemistry School, University of Buenos Aires, Buenos Aires, Argentina. danielgm@ffyb.uba.ar
Paz
Mariela L
ML
Ferrari
Alejandro
A
Weill
Federico S
FS
Nieto
Jorge
J
Leoni
Juliana
J
D000894:Anti-Inflammatory Agents, Non-Steroidal; D015232:Dinoprostone / Q000032:analysis; D007109:Immunity; D007165:Immunosuppression Therapy; D009288:Naproxen / Q000627:therapeutic use*; D012867:Skin / Q000276:immunology*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology / Q000517:prevention & control; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis; D014466:Ultraviolet Rays / Q000009:adverse effects*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D014409:Tumor Necrosis Factor-alpha; D009288:Naproxen; D015232:Dinoprostone